Eli Lilly’s selective estrogen receptor degrader (SERD) imlunestrant has shown a benefit in a potentially large indication – as a treatment for patients with ER+/HER2- advanced breast cancer who have progressed on an aromatase inhibitor (AI), with or without a CDK4/6 inhibitor like Lilly’s own Verzenio (abemaciclib) – but the bigger benefit is in combination.
Lilly’s Imlunestrant Shows Breast Cancer Benefit With Verzenio In All Comers
A Phase III trial testing the oral SERD showed a PFS benefit in ER+/HER2- advanced breast cancer in combination with a CDK4/6 inhibitor regardless of mutation status.
